Contents

Search


nabiximols (Sativex, Cannador)

Schedule 1 drug*. Approved for use in Canada Indications: - neuropathic pain from multiple sclerosis - cannabis dependence?* [2] * in combination with motivational enhancement therapy & cognitive behavioral therapy Contraindications: 1) absolute a) hypersensitivity to cannabinoids, ethanol, propylene glycol, or peppermint oil b) patients who are nursing or pregnant 2) relative a) significant hepatic or renal dysfunction b) history of a psychotic disorder (e.g., schizophrenia) - discontinue use with psychotic episode while on Sativex c) under 18 years of age d) women of child-bearing age not on a reliable form of contraceptive e) men expecting to start a family f) patients with severe cardiovascular disease - ischemic heart disease, - arrhythmias - poorly controlled hypertension - heart failure Dosage: 1) 100 uL peppermint-flavoured buccal spray (under the tongue or inside the cheek) delivers a) 2.7 mg of tetrahydrocannabinol b) 2.5 mg of cannabidiol 2) 1 spray every 4 hours; max 4 sprays on day 1 3) gradually adjust as needed 4) median daily dose of 5 sprays/day in clinical trials 5) limited experience > 12 sprays/day, but higher doses tolerated 5.5 mL vial. stored in the refrigerator (2-8 C) once opened, may be stored at room temperature (15-25 C) discard after 28 days Adverse effects: 1) generally mild to moderate# 2) gastrointestional - nausea, vomiting, diarrhea, sensation of heaviness dysgeusia, thirst, increased appetite, 3) neuromuscular - fatigue, weakness, lethary, falls, vertigo 4) CNS - feeling drunk, disturbance in attention, somnolence, dizziness, disorientation, dissociation, euphoria - subjects not able to subjectively distinguish nabiximols from placebo [2] 5) respiratory tract - cough, pharyngitis 6) cardiovascular - tachycardia, transient changes in blood pressure 7) local application site reaction* - dry mouth, oral pain, stinging * avoid spraying onto sore or inflamed mucous membranes # dose-related with increasing incidence at higher doses symptoms generally resolve with reducing the dose Drug interactions: 1) see dronabinol & cannabidiol 2) avoid concurrent administration of hypnotics Pharmacokinetics: - fast onset of action like smoked marijauna without smoke Mechanism of action: - contains delta-9 tetrahydrocannabinol & cannabidiol * Importation into US is illegal.

General

pharmacologic combination

Database Correlations

PUBCHEM cid=44148067

References

  1. Prescriber's Letter 12(6):32 2005 New Drug: Sativex (Delta-9-tetrahydrocannabinol and Cannabidiol) Detail-Document#: 210605 (subscription needed) http://www.prescribersletter.com
  2. Trigo JM, Soliman A, Quilty LC et al. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLoS One 2018 Jan 31; 13:e0190768. PMID: 29385147 Free PMC Article http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0190768

Components

cannabidiol (Epidiolex, Zygel, ZYN002, CBD) tetrahydrocannabinol; delta-9-tetrahydrocannabinol; THC